Enveric Biosciences Inc (ENVB)
0.84
-0.06
(-6.67%)
USD |
NASDAQ |
May 17, 16:00
0.8228
-0.02
(-2.05%)
After-Hours: 20:00
Enveric Biosciences Enterprise Value: 3.839M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 3.839M |
| May 16, 2024 | 4.277M |
| May 15, 2024 | 3.460M |
| May 14, 2024 | 3.697M |
| May 13, 2024 | 3.843M |
| May 10, 2024 | 4.204M |
| May 09, 2024 | 4.422M |
| May 08, 2024 | 4.860M |
| May 07, 2024 | 4.204M |
| May 06, 2024 | 4.422M |
| May 03, 2024 | 4.860M |
| May 02, 2024 | 4.463M |
| May 01, 2024 | 4.494M |
| April 30, 2024 | 4.568M |
| April 29, 2024 | 4.640M |
| April 26, 2024 | 4.240M |
| April 25, 2024 | 4.277M |
| April 24, 2024 | 4.525M |
| April 23, 2024 | 4.258M |
| April 22, 2024 | 3.992M |
| April 19, 2024 | 4.135M |
| April 18, 2024 | 4.554M |
| April 17, 2024 | 4.145M |
| April 16, 2024 | 4.357M |
| April 15, 2024 | 4.433M |
| Date | Value |
|---|---|
| April 12, 2024 | 5.079M |
| April 11, 2024 | 4.352M |
| April 10, 2024 | 4.482M |
| April 09, 2024 | 4.577M |
| April 08, 2024 | 4.423M |
| April 05, 2024 | 4.495M |
| April 04, 2024 | 4.649M |
| April 03, 2024 | 5.079M |
| April 02, 2024 | 6.027M |
| April 01, 2024 | 4.204M |
| March 28, 2024 | 5.006M |
| March 27, 2024 | 5.152M |
| March 26, 2024 | 5.444M |
| March 25, 2024 | 5.371M |
| March 22, 2024 | 5.954M |
| March 21, 2024 | 6.246M |
| March 20, 2024 | 4.294M |
| March 19, 2024 | 4.407M |
| March 18, 2024 | 3.901M |
| March 15, 2024 | 3.788M |
| March 14, 2024 | 3.901M |
| March 13, 2024 | 4.238M |
| March 12, 2024 | 4.463M |
| March 11, 2024 | 4.836M |
| March 08, 2024 | 5.322M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-16.97M
Minimum
Dec 28 2022
87.75M
Maximum
Feb 11 2021
9.194M
Average
8.822M
Median
Jan 21 2020
Enterprise Value Benchmarks
| Societal CDMO Inc (DELISTED) | 145.26M |
| Seelos Therapeutics Inc | 16.50M |
| Cardiff Oncology Inc | 95.16M |
| BioVie Inc | 9.577M |
| Adial Pharmaceuticals Inc | 3.458M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.436M |
| Total Expenses (Quarterly) | 4.233M |
| EPS Diluted (Quarterly) | -1.47 |
| Earnings Yield | -966.7% |
| Normalized Earnings Yield | -76469.90 |